Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis.
Joosten PJM, Dickhoff C, van der Noort V, Smeekens M, Numan RC, Klomp HM, van Diessen JNA, Belderbos JSA, Smit EF, Monkhorst K, Oosterhuis JWA, van den Heuvel MM, Dahele M, Hartemink KJ. Joosten PJM, et al. Among authors: van diessen jna. Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):566-575. doi: 10.1093/icvts/ivab291. Interact Cardiovasc Thorac Surg. 2022. PMID: 34734237 Free PMC article.
Radiotherapy dose and fractionation for stage III NSCLC.
Belderbos J, Walraven I, van Diessen J, Verheij M, de Ruysscher D. Belderbos J, et al. Lancet Oncol. 2015 Apr;16(4):e156-7. doi: 10.1016/S1470-2045(15)70121-X. Lancet Oncol. 2015. PMID: 25846093 No abstract available.
Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab.
Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, Koppe F, Codrington H, Kunst P, Dieleman E, van de Vaart P, Verheij M, Belderbos J. Walraven I, et al. Radiother Oncol. 2016 Mar;118(3):442-6. doi: 10.1016/j.radonc.2016.02.011. Epub 2016 Feb 15. Radiother Oncol. 2016. PMID: 26900091 Clinical Trial.
The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J, De Ruysscher D, Sonke JJ, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J. van Diessen J, et al. Radiother Oncol. 2019 Feb;131:166-173. doi: 10.1016/j.radonc.2018.09.019. Epub 2018 Oct 13. Radiother Oncol. 2019. PMID: 30327236 Clinical Trial.
Local and regional treatment response by 18FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC.
van Diessen JNA, La Fontaine M, van den Heuvel MM, van Werkhoven E, Walraven I, Vogel WV, Belderbos JSA, Sonke JJ. van Diessen JNA, et al. Among authors: van werkhoven e, van den heuvel mm. Radiother Oncol. 2020 Feb;143:30-36. doi: 10.1016/j.radonc.2019.10.008. Epub 2019 Nov 22. Radiother Oncol. 2020. PMID: 31767474 Clinical Trial.
In response to Park, et al.
van Diessen JNA, Kwint MH, Sonke JJ, Belderbos JSA. van Diessen JNA, et al. Radiother Oncol. 2020 Jun;147:245-246. doi: 10.1016/j.radonc.2020.03.036. Epub 2020 Apr 4. Radiother Oncol. 2020. PMID: 32312603 No abstract available.
24 results